Genentech To Get Chunk Of Regeneron’s Eylea Revenue Under Patent Settlement
Regeneron agrees to pay royalties on Eylea sales through May 7, 2016; analysts predict total payments will be $100 million to $140 million. Genentech’s suit alleging Zaltrap infringement remains pending.
You may also be interested in...
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.